Jiangsu Aikon Biopharmaceuticals

Aikon Biopharma is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on therapeutic areas such as metabolic diseases, specifically gout and hyperuricemia, and oncology. Aikon leverages its proprietary drug discovery platform to advance a pipeline of candidates, including its lead program AK-1012, a URAT1 inhibitor. In addition to its internal R&D, the company provides high-end chemistry services and CRO/CDMO support to global pharmaceutical partners. The firm is led by a management team with extensive international experience and is backed by prominent Chinese venture capital investors.